Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression
Corresponding Author
Y. Ebihara
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Address correspondence to: Dr Y. Ebihara, Department of Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine. North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060–8648 Japan. Tel: +81 11 716 1161; Fax: +81 11 706 7158; Email: [email protected]Search for more papers by this authorM. Miyamoto
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorT. Shichinohe
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorY. Kawarada
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorY. Cho
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorA. Fukunaga
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorS. Murakami
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorH. Uehara
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorH. Kaneko
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorH. Hashimoto
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorY. Murakami
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorT. Itoh
Department of Pathology, Hokkaido University Hospital, Hokkaido, Japan
Search for more papers by this authorS. Okushiba
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorS. Kondo
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorH. Katoh
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorCorresponding Author
Y. Ebihara
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Address correspondence to: Dr Y. Ebihara, Department of Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine. North 15, West 7, Kita-ku, Sapporo, Hokkaido, 060–8648 Japan. Tel: +81 11 716 1161; Fax: +81 11 706 7158; Email: [email protected]Search for more papers by this authorM. Miyamoto
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorT. Shichinohe
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorY. Kawarada
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorY. Cho
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorA. Fukunaga
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorS. Murakami
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorH. Uehara
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorH. Kaneko
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorH. Hashimoto
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorY. Murakami
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorT. Itoh
Department of Pathology, Hokkaido University Hospital, Hokkaido, Japan
Search for more papers by this authorS. Okushiba
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorS. Kondo
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorH. Katoh
Surgical Oncology, Cancer Medicine, Division of Cancer Medicine, Hokkaido University Graduate School of Medicine, and
Search for more papers by this authorAbstract
SUMMARY. The transcription factor E2F-1, a downstream regulator of the p16–cyclinD–Rb pathway, is required for cell cycle progression. Evidence shows that overexpression of E2F-1 can either promote or inhibit the development of tumors, depending on tissue or experimental conditions. However, the clinical impact of E2F-1 expression on esophageal squamous cell carcinoma (ESCC) remains unknown. To analyze E2F-1 expression in ESCC, we investigated the immunoreactivity of E2F-1 and its correlation with clinicopathological features in 122 patients who underwent surgical resection for ESCC. Positive E2F-1 immunostaining was detected in 73 patients (59.8%). Positive E2F-1 immunostaining correlated positively with pathologic stage (P = 0.0103), p-Grade (P = 0.0014) and pT (P = 0.0192). The overall survival rate was worse in patients with E2F-1-positive tumors than in patients with E2F-1-negative tumors (P = 0.0290). Over-expression of E2F-1 is associated with tumor progression and a worse prognosis after surgery in ESCC.
References
- 1 Collard J M, Otte J B, Fiasse R et al. Skeletonizing en bloc esophagectomy for cancer. Ann Surg 2001; 234: 25–32.
- 2 Ando N, Iizuka T, Kakegawa T et al. A randomized trial of surgery with and without chemotherapy for localized squamous carcinoma of the thoracic esophagus: the Japan Clinical Oncology Group Study. J Thorac Cardiovasc Surg 1997; 114: 205–9.
- 3 Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 2000; 232: 225–32.
- 4 Weinberg R A. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–30.
- 5 Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996; 8: 805–14.
- 6 Sherr C J. Cancer cell cycles. Science (Washington DC) 1996; 274: 1672–7.
- 7 Johnson D G, Schwarz J K, Cress W D, Nevins J R. Expression of transcription factor E2F-1 induces quiescent cells to enter S phase. Nature (London) 1993; 365: 349–52.
- 8 Degregori J, Leone G, Ohtani K, Miron A, Nevins J R. E2F1 accumulation bypasses a G1 arrest resulting from the inhibition of G1 cyclin-dependent kinase activity. Genes Dev 1995; 9: 2873–87.
- 9
Suzuki T,
Yasui W,
Yokozaki H,
Naka K,
Ishikawa T,
Tahara E.
Expression of the E2F family in human gastrointestinal carcinomas.
Int J Cancer
1999; 81: 535–8.
10.1002/(SICI)1097-0215(19990517)81:4<535::AID-IJC5>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- 10 Lai R, Medeiros L J, Coupland R, McCourty A, Brynes R K. Immunohistochemical detection of E2F-1 in non-Hodgikin's lymphomas: a survey of 124 cases. Mod Pathol 1998; 11: 457–63.
- 11 Saunders N A, Dicker A J, Jones S J, Dahler A L. E2F1 messenger RNA is destabilized in response to a growth inhibitor in normal human keratinocytes but not in a squamous carcinoma cell line. Cancer Res 1998; 58: 1646–9.
- 12 Jones S J, Dicker A J, Dahlar A L, Saunter N A. E2F as a regulator of keratinocyte proliferation: implications for skin tumor development. J Invest Dermatol 1997; 109: 187–93.
- 13 Qin X Q, Livingston D M, Kaelin W G, Adams P D. Deregulated transcription factor E2F-1 expression leads to S-phase and p53-mediated apoptosis. Proc Nat Acad Sci USA 1994; 91: 10918–22.
- 14 Hunt K K, Deng J, Liu T J et al. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian-carcinoma cell lines and dose not require p53. Cancer Res 1997; 57: 4722–6.
- 15
Dong Y B,
Yang H L,
Elliott M J et al.
Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells.
Cancer (Phila) 1999; 86: 2021–33.
10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1 CAS PubMed Web of Science® Google Scholar
- 16 Yamazaki L, Jack T, Bronson R, Goillot E, Harlow E, Dyson N J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 1996; 85: 539–48.
- 17 Rabbani F, Richon V M, Orlow I et al. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J Natl Cancer Inst 1999; 91: 874–81.
- 18 Zhang S Y, Liu S C, Al-Saleem L F et al. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol Biomark Prev 2000; 9: 395–401.
- 19 Banerjee D, Richchard G, Liefshitz A et al. Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res 2000; 60: 2365–7.
- 20 Sobin L H, Wittekind Ch, (eds). International Union Against Cancer, TNM. Classification of Malignant Tumor, 6th edn. New York: Wiley-Liss, 2002; pp. 60–4.
- 21 Volante Marco, Croce Sabrina, Pecchioni Carla, Papotti Mauro. E2F-1 Transcription Factor Is overexpressed in Oxyphilic Thyroid Tumors. Mod Pathol 2002; 15: 1038–43.
- 22 Saiz Antonio D, Olvera Maria, Rezk Sherif, Florentine Barbara A, McCoutry Althea, Byrnes Russell K. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions. J Pathol 2002; 198: 157–62.
- 23 Lai R, Mederiros L J, Wilson C S et al. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf-1, and Ki-67 in multiple myeloma. Mod Pathol 1998; 11: 642–7.
- 24 Slansky J E, Farnham P J. Introduction to E2F family: protein structure and gene regulation. Curr Top Microbiol Immunol 1996; 208: 1–30.
- 25 Johnson D G, Cress W D, Jkoi L, Nevins J R. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 1994; 91: 12823–7.
- 26 Saito M, Helin K, Valentine M B, Griffith B B, Willman C L, Harlow E. Amplification of the E2F-1 transcription gene in the HEL erytholeukemia cell line. Genomics 1995; 25: 130–8.
